Tackling non-muscle invasive bladder cancer in the clinic

References

• Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr
   Google Scholar
• Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234–241.
   PubMed Web of Science ®Google Scholar
• Freedman ND, Silverman DT, Hollenbeck AR, et al. Association between smoking and risk of bladder cancer among men and women. Jama. 2011;306(7):737–745.
   PubMed Web of Science ®Google Scholar
• Rushton L, Hutchings SJ, Fortunato L, et al. Occupational cancer burden in Great Britain. Br J Cancer. 2012;107(Suppl 1):S3–7.
   PubMed Web of Science ®Google Scholar
• Cumberbatch MG, Cox A, Teare D, et al. Contemporary occupational carcinogen exposure and bladder cancer: a systematic review and meta-analysis. JAMA Oncol. 2015;1(9):1282–1290.
   PubMed Web of Science ®Google Scholar
• Stenzl A, Hennenlotter J, Schilling D. Can we still afford bladder cancer? Curr Opin Urol. 2008;18(5):488–492.
   PubMed Web of Science ®Google Scholar
• Wijkstrom H, Cohen SM, Gardiner RA, et al. Prevention and treatment of urothelial premalignant and malignant lesions. Scand J Urol Nephrol Suppl. 2000;205:116–135.
   Google Scholar
• Khadra MH, Pickard RS, Charlton M, et al. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol. 2000;163(2):524–527.
   PubMed Web of Science ®Google Scholar
• Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. Jama. 2005;293(7):810–816.
   PubMed Web of Science ®Google Scholar
• Mariani AJ, Mariani MC, Macchioni C, et al. The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol. 1989;141(2):350–355.
   PubMed Web of Science ®Google Scholar
• Davis R, Jones JS, Barocas DA, et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol. 2012;188(6 Suppl):2473–2481.
   PubMed Web of Science ®Google Scholar
• Messing EM, Young TB, Hunt VB, et al. Home screening for hematuria: results of a multiclinic study. J Urol. 1992;148(2 Pt 1):289–292.
   PubMed Web of Science ®Google Scholar
• O’Donnell MA. Advances in the management of superficial bladder cancer. Semin Oncol. 2007;34(2):85–97.
   PubMed Web of Science ®Google Scholar
• Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology. 2003;61(1):109-118; discussion 118.
   PubMed Web of Science ®Google Scholar
• Mbeutcha A, Lucca I, Mathieu R, et al. Current status of urinary biomarkers for detection and surveillance of bladder cancer. Urol Clin North Am. 2016;43(1):47–62.
   PubMed Web of Science ®Google Scholar
• Dahm P, Gschwend JE. Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur Urol. 2003;44(6):672–681.
   PubMed Web of Science ®Google Scholar
• Woldu SL, Bagrodia A, Lotan Y. Guideline of guidelines - non-muscle invasive bladder cancer. BJU Int. 2017 Mar;119(3):371–380.
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC, Ag F, et al., ed. AJCC cancer staging manual. New York, NY: Springer; 2010.
   Google Scholar
• Sobin LH, Wittekind C, ed. UICC international union against cancer. Hoboken, NJ: Wiley-Blackwell; 2009.
   Google Scholar
• Eble J, Epstein J, Sesterhenn I. The World Health Organization classification of tumors of the urinary system and male genital system. Lyon, France: IARC Press; 2004.
   Google Scholar
• Mostofi FSL, Torloni H. Histological typing of urinary bladder tumors. In International classification of tumors, 1st. Geneva, Switzerland: World Health Organization; 1973.
   Google Scholar
• Moch H, Ulbright TM, Reuter V. WHO classification of tumours of the urinary system and male genital organs. Lyon, France: International Agency for Research on Cancer; 2016.
   Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–467.
   PubMed Web of Science ®Google Scholar
• Clark P, SPiess PR, Agarway N, et al. NCCN clinical practice guidelines in oncology bladder cancer version 2. Ed.^(Eds). National Comprehensive Cancer Network, Inc.; 2016. Available at: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
   Google Scholar
• Babjuk M, Bohle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017 Mar;71(3):447–461.
   Google Scholar
• Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196(4):1021–1029.
   PubMed Web of Science ®Google Scholar
• Herr HW, Donat SM. Quality control in transurethral resection of bladder tumours. BJU Int. 2008;102(9 Pt B):1242–1246.
   PubMed Web of Science ®Google Scholar
• Mariappan P, Zachou A, Grigor KM. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol. 2010;57(5):843–849.
   PubMed Web of Science ®Google Scholar
• Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41(5):523–531.
   PubMed Web of Science ®Google Scholar
• Fritsche HM, Burger M, Svatek RS, et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol. 2010;57(2):300–309.
   PubMed Web of Science ®Google Scholar
• Divrik RT, Yildirim U, Zorlu F, et al. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol. 2006;175(5):1641–1644.
   PubMed Web of Science ®Google Scholar
• Sfakianos JP, Kim PH, Hakimi AA, et al. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guerin. J Urol. 2014;191(2):341–345.
   PubMed Web of Science ®Google Scholar
• Schmidbauer J, Witjes F, Schmeller N, et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol. 2004;171(1):135–138.
   PubMed Web of Science ®Google Scholar
• Kamat AM, Cookson M, Witjes JA, et al. The impact of blue light cystoscopy with hexaminolevulinate (HAL) on progression of bladder cancer - a new analysis. Bladder Cancer. 2016;2(2):273–278.
   PubMedGoogle Scholar
• Burger M, Grossman HB, Droller M, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013;64(5):846–854.
   PubMed Web of Science ®Google Scholar
• Zheng C, Lv Y, Zhong Q, et al. Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU Int. 2012;110(11 Pt B):E680–687.
   PubMed Web of Science ®Google Scholar
• Naselli A, Introini C, Timossi L, et al. A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. Eur Urol. 2012;61(5):908–913.
   PubMed Web of Science ®Google Scholar
• Sonn GA, Jones SN, Tarin TV, et al. Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy. J Urol. 2009;182(4):1299–1305.
   PubMed Web of Science ®Google Scholar
• Goh AC, Tresser NJ, Shen SS, et al. Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. Urology. 2008;72(1):133–137.
   PubMed Web of Science ®Google Scholar
• Kurth KH, Denis L, Bouffioux C, et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer. 1995;31a(11):1840–1846.
   PubMed Web of Science ®Google Scholar
• Heney NM. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am. 1992;19(3):429–433.
   PubMed Web of Science ®Google Scholar
• Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195–2203.
   PubMed Web of Science ®Google Scholar
• Cambier S, Sylvester RJ, Collette L, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus calmette-guerin. Eur Urol. 2016;69(1):60–69.
   PubMed Web of Science ®Google Scholar
• Krabbe LM, Woldu SL, Shariat SF, et al. Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence. Expert Rev Mol Diagn. 2016;16(11):1189–1199.
   PubMed Web of Science ®Google Scholar
• Kavalieris L, O’Sullivan P, Frampton C, et al. Performance characteristics of a multigene urine biomarker test for monitoring for recurrent urothelial carcinoma in a multicenter study. J Urol. 2016 Dec 14. pii: S0022-5347(16)31930–9. doi: 10.1016/j.juro.2016.12.010. [Epub ahead of print].
   Google Scholar
• Gayed BA, Seideman C, Lotan Y. Cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma. J Urol. 2013;190(4):1181–1186.
   PubMed Web of Science ®Google Scholar
• Lotan Y, Bensalah K, Ruddell T, et al. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol. 2008;179(6):2164–2169.
   PubMed Web of Science ®Google Scholar
• Kamat AM, Willis DL, Dickstein RJ, et al. Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guerin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. BJU Int. 2016;117(5):754–760.
   PubMed Web of Science ®Google Scholar
• Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol. 2008;179(1):53–56.
   PubMed Web of Science ®Google Scholar
• Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180–183.
   PubMed Web of Science ®Google Scholar
• Lamm DL, Thor DE, Harris SC, et al. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol. 1980;124(1):38–40.
   PubMed Web of Science ®Google Scholar
• Camacho F, Pinsky C, Kerr D, et al. Treatment of superficial bladder cancer with intravesical BCG (abstract C-160). Proc Am Assoc Cancer Res Am Soc Clin Oncol. 1980;21:359. [Ed.^(Eds)].
   Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–218.
   PubMed Web of Science ®Google Scholar
• Donin NM, Lenis AT, Holden S, et al. Immunotherapy for the treatment of Urothelial Carcinoma. J Urol. 2017;197(1):14–22.
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124–1129.
   PubMed Web of Science ®Google Scholar
• Palou J, Laguna P, Millan-Rodriguez F, et al. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol. 2001;165(5):1488–1491.
   PubMed Web of Science ®Google Scholar
• Hudson MA, Ratliff TL, Gillen DP, et al. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol. 1987;138(2):295–298.
   PubMed Web of Science ®Google Scholar
• Badalament RA, Herr HW, Wong GY, et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol. 1987;5(3):441–449.
   PubMed Web of Science ®Google Scholar
• Brausi M, Oddens J, Sylvester R, et al. Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014;65(1):69–76.
   PubMed Web of Science ®Google Scholar
• Lamm DL, Van Der Meijden PM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol. 1992;147(3):596–600.
   PubMed Web of Science ®Google Scholar
• Rischmann P, Desgrandchamps F, Malavaud B, et al. BCG intravesical instillations: recommendations for side-effects management. Eur Urol. 2000;37(Suppl 1):33–36.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Dalbagni G, Karnes RJ, et al. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. Urol Oncol. 2016;34(11):484.e19-484.e25.
   Web of Science ®Google Scholar
• Sylvester RJ, Van Der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964–1970.
   PubMed Web of Science ®Google Scholar
• Malmstrom PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247–256.
   PubMed Web of Science ®Google Scholar
• Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology. 2004;63(4):682-686; discussion 686-687.
   Web of Science ®Google Scholar
• Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57(5):766–773.
   PubMed Web of Science ®Google Scholar
• Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63(3):462–472.
   PubMed Web of Science ®Google Scholar
• Lerner SP, Dinney C, Kamat A, et al. Clarification of bladder cancer disease states following treatment of patients with intravesical BCG. Bladder Cancer. 2015;1(1):29–30.
   PubMed Web of Science ®Google Scholar
• Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol. 2003;169(5):1706–1708.
   PubMed Web of Science ®Google Scholar
• O’Donnell MA, Boehle A. Treatment options for BCG failures. World J Urol. 2006;24(5):481–487.
   PubMed Web of Science ®Google Scholar
• Nieder AM, Brausi M, Lamm D, et al. Management of stage T1 tumors of the bladder: international Consensus Panel. Urology. 2005;66(6 Suppl 1):108–125.
   PubMed Web of Science ®Google Scholar
• Burger M, Oosterlinck W, Konety B, et al. ICUD-EAU international consultation on bladder cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63(1):36–44.
   PubMed Web of Science ®Google Scholar
• Gupta A, Lotan Y, Bastian PJ, et al. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology. 2008;71(2):302–307.
   PubMed Web of Science ®Google Scholar
• Tilki D, Reich O, Svatek RS, et al. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol. 2010;183(5):1757–1763.
   PubMed Web of Science ®Google Scholar
• Jager W, Thomas C, Haag S, et al. Early vs delayed radical cystectomy for ‘high-risk’ carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survival. BJU Int. 2011;108(8 Pt 2):E284–288.
   Google Scholar
• Kamat AM, Gee JR, Dinney CP, et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol. 2006;175(3 Pt 1):881–885.
   PubMed Web of Science ®Google Scholar
• Abrams PH, Choa RG, Gaches CG, et al. A controlled trial of single dose intravesical adriamycin in superficial bladder tumours. Br J Urol. 1981;53(6):585–587.
   PubMedGoogle Scholar
• Zargar H, Aning J, Ischia J, et al. Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer. Nat Rev Urol. 2014;11(4):220–230.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171(6 Pt 1):2186–2190, quiz 2435.
   PubMed Web of Science ®Google Scholar
• Perlis N, Zlotta AR, Beyene J, et al. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. Eur Urol. 2013;64(3):421–430.
   PubMed Web of Science ®Google Scholar
• Cookson MS, Chang SS, Oefelein MG, et al. National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer. J Urol. 2012;187(5):1571–1576.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, Holmang S, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the Instillation? Eur Urol. 2016;69(2):231–244.
   PubMed Web of Science ®Google Scholar
• Johnson DC, Pruthi RS, Woods ME. Perioperative chemotherapy: when to use it, what to use, and why. Urol Clin North Am. 2013;40(2):183–195.
   PubMed Web of Science ®Google Scholar
• Huncharek M, Geschwind JF, Witherspoon B, et al. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol. 2000;53(7):676–680.
   PubMed Web of Science ®Google Scholar
• Lamm DL, Riggs DR, Traynelis CL, et al. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol. 1995;153(5):1444–1450.
   PubMed Web of Science ®Google Scholar
• Meyer JP, Persad R, Gillatt DA. Use of bacille Calmette-Guerin in superficial bladder cancer. Postgrad Med J. 2002;78(922):449–454.
   PubMed Web of Science ®Google Scholar
• Bradner WT. Mitomycin C: a clinical update. Cancer Treat Rev. 2001;27(1):35–50.
   PubMed Web of Science ®Google Scholar
• Bolenz C, Cao Y, Arancibia MF, et al. Intravesical mitomycin C for superficial transitional cell carcinoma. Expert Rev Anticancer Ther. 2006;6(8):1273–1282.
   PubMed Web of Science ®Google Scholar
• Bateman JC. Chemotherapy of solid tumors with triethylene thiophosphoramide. N Engl J Med. 1955;252(21):879–887.
   PubMed Web of Science ®Google Scholar
• Heney NM, Koontz WW, Barton B, et al. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. J Urol. 1988;140(6):1390–1393.
   PubMed Web of Science ®Google Scholar
• Heney NM. First-line chemotherapy of superficial bladder cancer: mitomycin vs thiotepa. Urology. 1985;26(4 Suppl):27–29.
   PubMed Web of Science ®Google Scholar
• Onrust SV, Wiseman LR, Goa KL. Epirubicin: a review of its intravesical use in superficial bladder cancer. Drugs Aging. 1999;15(4):307–333.
   PubMed Web of Science ®Google Scholar
• Pavone-Macaluso M, Tripi M, Ingargiola GB, et al. Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin. J Chemother. 1993;5(3):207–211.
   PubMed Web of Science ®Google Scholar
• Shinohara N, Nonomura K, Tanaka M, et al. Prophylactic chemotherapy with anthracyclines (adriamycin, epirubicin, and pirarubicin) for primary superficial bladder cancer. The Hokkaido University bladder cancer collaborative group. Cancer Chemother Pharmacol. 1994;35:Suppl, S41–45.
   Google Scholar
• Malmstrom PU, Wijkstrom H, Lundholm C, et al. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian bladder cancer study group. J Urol. 1999;161(4):1124–1127.
   PubMed Web of Science ®Google Scholar
• Barlow LJ, Benson MC. Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer. Curr Urol Rep. 2013;14(2):65–70.
   PubMed Web of Science ®Google Scholar
• Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000;163(3):761–767.
   PubMed Web of Science ®Google Scholar
• Dinney CP, Greenberg RE, Steinberg GD. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin. Urol Oncol. 2013;31(8):1635–1642.
   PubMed Web of Science ®Google Scholar
• Jones G, Cleves A, Wilt TJ, et al. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2012;1:Cd009294.
   PubMedGoogle Scholar
• Shelley M, Cleves A, Wilt TJ, et al. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer. Cochrane Database Syst Rev. 2011;4:Cd008976.
   Google Scholar
• Gontero P, Casetta G, Maso G, et al. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol. 2004;46(3):339–343.
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006;24(18):2729–2734.
   PubMed Web of Science ®Google Scholar
• Serretta V, Galuffo A, Pavone C, et al. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: phase I-II study on marker lesions. Urology. 2005;65(1):65–69.
   PubMed Web of Science ®Google Scholar
• Bartoletti R, Cai T, Gacci M, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology. 2005;66(4):726–731.
   PubMed Web of Science ®Google Scholar
• Addeo R, Caraglia M, Bellini S, et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol. 2010;28(4):543–548.
   PubMed Web of Science ®Google Scholar
• Porena M, del Zingaro M, Lazzeri M, et al. Bacillus Calmette-Guerin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study. Urol Int. 2010;84(1):23–27.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Perdona S, Damiano R, et al. Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer. 2010;116(8):1893–1900.
   PubMed Web of Science ®Google Scholar
• Lamm D, Brausi M, O’Donnell MA, et al. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. Urol Oncol. 2014;32(1):35.e21-30.
   PubMed Web of Science ®Google Scholar
• Torti FM, Shortliffe LD, Williams RD, et al. Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. J Clin Oncol. 1988;6(3):476–483.
   PubMed Web of Science ®Google Scholar
• Portillo J, Martin B, Hernandez R, et al. Results at 43 months’ follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. Urology. 1997;49(2):187–190.
   PubMed Web of Science ®Google Scholar
• Boccardo F, Cannata D, Rubagotti A, et al. Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. J Clin Oncol. 1994;12(1):7–13.
   PubMed Web of Science ®Google Scholar
• Jimenez-Cruz JF, Vera-Donoso CD, Leiva O, et al. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guerin and interferon-alpha. Urology. 1997;50(4):529–535.
   PubMed Web of Science ®Google Scholar
• Luo Y, Chen X, Downs TM, et al. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy. J Immunol. 1999;162(4):2399–2405.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Agrawal U, Verma S, et al. Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy. Immunopharmacol Immunotoxicol. 2010;32(2):348–356.
   PubMed Web of Science ®Google Scholar
• Nepple KG, Lightfoot AJ, Rosevear HM, et al. Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol. 2010;184(5):1915–1919.
   PubMed Web of Science ®Google Scholar
• Joudi FN, Smith BJ, O’Donnell MA. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol. 2006;24(4):344–348.
   PubMed Web of Science ®Google Scholar
• Joudi FN, Smith BJ, O’Donnell MA, et al. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol. 2006;175(5):1634-1639; discussion 1639-1640.
   PubMed Web of Science ®Google Scholar
• Gallagher BL, Joudi FN, Maymi JL, et al. Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy. Urology. 2008;71(2):297–301.
   PubMed Web of Science ®Google Scholar
• Rosevear HM, Lightfoot AJ, Birusingh KK, et al. Factors affecting response to bacillus Calmette-Guerin plus interferon for urothelial carcinoma in situ. J Urol. 2011;186(3):817–823.
   PubMed Web of Science ®Google Scholar
• de Wit R, Kruit WH, Stoter G, et al. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer. 1998;78(10):1342–1345.
   PubMed Web of Science ®Google Scholar
• Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guerin therapy. J Urol. 2013;189(3):834–839.
   PubMed Web of Science ®Google Scholar
• McKiernan JM, Holder DD, Ghandour RA, et al. Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guerin treatment failure. J Urol. 2014;192(6):1633–1638.
   PubMed Web of Science ®Google Scholar
• Delto JC, Kobayashi T, Benson M, et al. Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression. Oncotarget. 2013;4(2):269–276.
   PubMed Web of Science ®Google Scholar
• Seraphim LA, Perrapato SD, Slocum HK, et al. In vitro study of the interaction of doxorubicin, thiotepa, and mitomycin-C, agents used for intravesical chemotherapy of superficial bladder cancer. J Urol. 1991;145(3):613–617.
   PubMed Web of Science ®Google Scholar
• Hadaschik BA, Ter Borg MG, Jackson J, et al. Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer. BJU Int. 2008;101(11):1347–1355.
   PubMed Web of Science ®Google Scholar
• Chen CH, Yang HJ, Shun CT, et al. A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer. Urol Oncol. 2012;30(4):421–427.
   PubMed Web of Science ®Google Scholar
• Wientjes MG, Badalament RA, Wang RC, et al. Penetration of mitomycin C in human bladder. Cancer Res. 1993;53(14):3314–3320.
   PubMed Web of Science ®Google Scholar
• van der Heijden AG, Kiemeney LA, Gofrit ON, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol. 2004;46(1):65–71.
   Web of Science ®Google Scholar
• Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003;21(23):4270–4276.
   PubMed Web of Science ®Google Scholar
• Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2011;60(1):81–93.
   PubMed Web of Science ®Google Scholar
• Arends TJ, Nativ O, Maffezzini M, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin c versus bacillus calmette-guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol. 2016;69(6):1046–1052.
   PubMed Web of Science ®Google Scholar
• Nativ O, Witjes JA, Hendricksen K, et al. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol. 2009;182(4):1313–1317.
   PubMed Web of Science ®Google Scholar
• Slater SE, Patel P, Viney R, et al. The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer. Ann R Coll Surg Engl. 2014;96(6):415–419.
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Massoud R, et al. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res. 1999;59(19):4912–4918.
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol. 2003;170(3):777–782.
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006;7(1):43–51.
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Valenti M, Verri C, et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol. 2011;12(9):871–879.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467–477.
   PubMed Web of Science ®Google Scholar
• Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182(2):459–465.
   PubMed Web of Science ®Google Scholar
• Wong RM, Scotland RR, Lau RL, et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol. 2007;19(10):1223–1234.
   PubMed Web of Science ®Google Scholar
• Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14(10):3044–3051.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21(19):4286–4293.
   PubMed Web of Science ®Google Scholar
• Beck A, Wurch T, Reichert JM. 6th Annual European Antibody Congress 2010: november 29-December 1, 2010, Geneva, Switzerland. MAbs. 2011;3(2):111–132.
   PubMedGoogle Scholar
• Boyerinas B, Jochems C, Fantini M, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3(10):1148–1157.
   PubMed Web of Science ®Google Scholar
• Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–562.
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–1920.
   PubMed Web of Science ®Google Scholar
• Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007;109(8):1499–1505.
   PubMed Web of Science ®Google Scholar
• Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci. 2016;107(10):1373–1379.
   PubMed Web of Science ®Google Scholar
• Burke JM, Lamm DL, Meng MV, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012;188(6):2391–2397.
   PubMed Web of Science ®Google Scholar
• Cold Genesys, Inc. Safety and efficacy of CG0070 oncolytic virus regimen for high grade NMIBC after BCG failure (BOND2). In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine. 2000. [cited 2017 Mar 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02365818
   Google Scholar
• Adam L, Black PC, Kassouf W, et al. Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. J Urol. 2007;177(5):1900–1906.
   PubMed Web of Science ®Google Scholar
• Navai N, Benedict WF, Zhang G, et al. Phase 1b trial to evaluate tissue response to a second dose of intravesical recombinant adenoviral interferon alpha2b formulated in syn3 for failures of Bacillus Calmette-Guerin (BCG) therapy in nonmuscle invasive bladder cancer. Ann Surg Oncol. 2016;23(12):4110–4114.
   PubMed Web of Science ®Google Scholar
• Dinney CP, Fisher MB, Navai N, et al. Phase I trial of intravesical recombinant adenovirus mediated interferon-alpha2b formulated in Syn3 for Bacillus Calmette-Guerin failures in nonmuscle invasive bladder cancer. J Urol. 2013;190(3):850–856.
   PubMed Web of Science ®Google Scholar
• Keehn A, Gartrell B, Schoenberg MP. Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer. Future Oncol. 2016;12(23):2673–2682.
   PubMed Web of Science ®Google Scholar
• Steinberg G, Shore ND, Karsh L, et al. Top-line results from vesigenurtacel-L (HS-410) in Combination with BCG from a randomized, blinded phase 2 trial in patients with Non-Muscle Invasive Bladder Cancer (NMIBC). In: Society of urologic oncology. Annual Meeting. San Antonio, Texas; 2016.
   Google Scholar
• Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014;32(34):3801–3809.
   PubMed Web of Science ®Google Scholar
• Harland SJ, Kynaston H, Grigor K, et al. A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. J Urol. 2007;178(3 Pt 1):807-813; discussion 813.
   PubMed Web of Science ®Google Scholar
• Weiss C, Wolze C, Engehausen DG, et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J Clin Oncol. 2006;24(15):2318–2324.
   PubMed Web of Science ®Google Scholar
• Saint F, Salomon L, Quintela R, et al. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guerin (BCG) immunotherapy exist? Analysis of a quarter century of literature. Eur Urol. 2003;43(4):351-360;discussion 360-351.
   Web of Science ®Google Scholar
• Kamat AM, Briggman J, Urbauer DL, et al. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to bacillus calmette-guerin. Eur Urol. 2016;69(2):197–200.
   PubMed Web of Science ®Google Scholar
• Pichler R, Fritz J, Zavadil C, et al. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical bacillus calmette-guerin therapy in bladder cancer. Oncotarget. 2016 Jun 28;7(26):39916–39930.
   PubMed Web of Science ®Google Scholar
• Lima L, Oliveira D, Ferreira JA, et al. The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guerin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population. BJU Int. 2015;116(5):753–763.
   PubMed Web of Science ®Google Scholar
• Rao S, Beckman RA, Riazi S, et al. Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment. Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13544. [Epub ahead of print].
   Google Scholar
• Hedegaard J, Lamy P, Nordentoft I, et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell. 2016;30(1):27–42.
   PubMed Web of Science ®Google Scholar